Home > News > 61/Iatrogenic cardiac perforation following pacemaker and defibrillator implantation; presentation, management and outcomes
Devices
Read Time: < 1 min

61/Iatrogenic cardiac perforation following pacemaker and defibrillator implantation; presentation, management and outcomes

Published Online: September 27th 2010 European Journal of Arrhythmia & Electrophysiology. 2020;6(Suppl. 1):abstr61
Authors: Peter Waddingham (Presenting Author) - St Bartholomew’s Hospital, Barts Health NHS Trust, London; A Creta - St Bartholomew’s Hospital, Barts Health NHS Trust, London; ASC Dennis - St Bartholomew’s Hospital, Barts Health NHS Trust, London; MJ Earley - St Bartholomew’s Hospital, Barts Health NHS Trust, London; P Moore - St Bartholomew’s Hospital, Barts Health NHS Trust, London; A Muthumala - St Bartholomew’s Hospital, Barts Health NHS Trust, London; AWC Chow - St Bartholomew’s Hospital, Barts Health NHS Trust, London
Quick Links:
Article
Article Information
Article:

Aims: Cardiac perforations caused by pacemaker and implantable-cardioverter defibrillator (ICD) leads are serious events. Due in part to their infrequency, management options and outcomes are unclear.

Methods: A single-centre retrospective study was conducted at a high-volume tertiary centre to identify patients in whom cardiac perforation occurred due to lead implantation or intervention. The search included all lead procedures spanning 3 years from 2016-2019. 6 months follow-up was assessed in all patients with perforation.

Results: Of 4619 procedures 32 patients were diagnosed with lead related cardiac perforation (involving 33 leads), mean age 74±15 years, 20 (63%) female, mean left ventricular ejection fraction 51% (±11). 9 devices were implanted at other centres; therefore, the institutional rate of perforation was 0.5% (n=23 patients, 24 leads). 9 (39%) were identified acutely (<24 hours), median time to diagnosis was 32 (±49) days in sub-acute/chronic perforation. All but one leads were active fixation models; 25/32 (78%) had abnormal electrical parameters at device interrogation. 6/33 (18%) were ICD leads. 27/33 (82%) leads perforated the right ventricle (RV) in the apex or anterior apical region, 3 (9%) mid anterior RV and 2 (6%) lateral right atrium. Management was trans-venous in 31/32 (97%) patients with lead extraction or repositioning; pericardial drainage was required in 10/32 (31%), sternotomy with surgical repair was required in 1 (3%). 1 (3%) patient was deceased within 30 days, all other patients made a full recovery and were well at 6 months follow-up.

Conclusion: Although infrequent (0.5%), perforation occurred predominantly in the RV apex. No clear patient factors were identified as risk factors. Trans-venous lead extraction was safe and effective with surgical intervention rarely required.

Article Information:

Further Resources

Share this Article
Related Content In Devices
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72